Wide Ranks

MDT

Medtronic plc.

86.27

Top Statistics
Market Cap 110 B Forward PE 14.77 Revenue Growth 2.80 %
Current Ratio 2.13 Trailing PE 26.38 Earnings Growth 35.60 %
Profit Margins 12.06 % Peg Ratio Dividend Yield 3.20 %
Enterprice / EBITA 14.71 Enterprise / Revenue 4.07 Price To Sales Trailing12 Months 3.40
Profitability
Profit Margins 12.06 % Operating Margins 17.51 %
Balance Sheet
Total Cash 7 B Total Cash Per Share 6.12 Total Debt 27 B
Total Debt To Equity 57.86 Current Ratio 2.13 Book Value Per Share 38.29
All Measures
Return On Equity 0.0795 Total Debt 27 B Beta 0.8530
Last Split Date 938 M Fifty Two Week Low 75.96 Audit Risk 8
Target Mean Price 96.43 Short Percent Of Float 0.0080 Trailing Peg Ratio 157.51 %
Last Fiscal Year End 1 B Average Volume10days 7 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0026 Ebitda Margins 27.67 % Trailing PE 26.38
Most Recent Quarter 1 B Gmt Off Set Milliseconds -18000000 Fifty Day Average 88.81
Open 86.13 Return On Assets 0.0442 Time Zone Short Name EST
Board Risk 6 Trailing Eps 3.27 Day Low 85.92
Shares Outstanding 1 B Compensation Risk 5 Price Hint 2
Website https://www.medtronic.com 52 Week Change 0.0883 Recommendation Key buy
Quick Ratio 134.70 % Last Split Factor 2:1 Is_sp_500 True
Profit Margins 12.06 % Debt To Equity 57.86 Fifty Two Week High 92.68
Enterprise To Revenue 4.07 Operating Cashflow 6 B Five Year Avg Dividend Yield 265.00 %
Market Cap 110 B Quote Type EQUITY Industry Medical Devices
Ex Dividend Date 1 B Overall Risk 6 Long Name Medtronic plc
Current Ratio 2.13 Number Of Analyst Opinions 28 Governance Epoch Date 1 B
Forward PE 14.77 Regular Market Volume 5 M Short Ratio 219.00 %
Message Board Id finmb_31348 Shares Short Prior Month 10 M City Galway
Uuid c9b9ae1b-4267-324d-8899-95d8371bbb3b Previous Close 85.68 First Trade Date Epoch Utc 105 M
Book Value 38.29 Volume 5 M Price To Book 2.25
Total Cash Per Share 6.12 Total Revenue 32 B Shares Short Previous Month Date 1 B
Target Median Price 97.00 Max Age 86400 Recommendation Mean 2.24
Sand P52 Week Change 0.3133 Operating Margins 17.51 % Last Dividend Value 0.7000
Net Income To Common 3 B Ask 86.80 Implied Shares Outstanding 1 B
Average Daily Volume10 Day 7 M Total Cash 7 B Revenue Per Share 24.71
Dividend Rate 2.80 Date Short Interest 1 B Share Holder Rights Risk 6
Regular Market Previous Close 85.68 Target Low Price 82.00 Free Cashflow 4 B
Dividend Yield 3.20 % Target High Price 112.00 Address1 Building Two
Average Volume 6 M Earnings Quarterly Growth 31.70 % Forward Eps 5.85
Compensation As Of Epoch Date 1 B Regular Market Day High 86.89 Day High 86.89
Shares Short 10 M Regular Market Open 86.13 Industry Key medical-devices
Bid 85.85 Earnings Growth 35.60 % Revenue Growth 2.80 %
Shares Percent Shares Out 0.0079 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Payout Ratio 93.27 % Regular Market Day Low 85.92
Held Percent Institutions 0.8542 Current Price 86.27 Address2 Parkmore Business Park West
Enterprise To Ebitda 14.71 Financial Currency USD Gross Margins 65.53 %
Industry Disp Medical Devices Country Ireland Float Shares 1 B
Two Hundred Day Average 84.47 Enterprise Value 132 B Price To Sales Trailing12 Months 3.40
Last Dividend Date 1 B Ebitda 9 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.

The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.

The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.

The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments.

The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products.

The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system.

The company was founded in 1949 and is headquartered in Galway, Ireland.